Research Article
Evaluation of the Periodontal Status in Acromegalic Patients: A Comparative Study
Table 1
Detailed clinical description of the 32 acromegalic patients studied.
| Patient | Age (years) |
Sex | Medication with | | | | CB | RA | LP | GB | BAA | AD | PG | HT | PA | TT | SC | IGF-I (ng/mL) | IGFBP-3 (ng/mL) | Comorbidities |
| I | 61 | Male | | | + | | | | + | | | + | + | 133 | 2980 | TH | II | 47 | Male | | | | | | | | | | | | 204 | 5870 | K | III | 61 | Male | | | | | | | | | | | | 727 | 8850 | D, H, C | IV | 57 | Male | | | | | | | | + | | + | + | 138 | 3960 | H | V | 48 | Male | | | | | | | | | | | | 118 | 3540 | | VI | 70 | Male | | | | | | | + | | | + | | 48.2 | 1910 | | VII | 52 | Male | | | | | | | | | | | | 75.4 | 5420 | | VIII | 48 | Male | | | | | | | | | | | | 92.1 | 2940 | H, TH | IX | 52 | Male | | | | | | | + | | | + | + | 104 | 3560 | TH | X | 67 | Male | | + | | | + | | | | | | | 624 | 5640 | H | XI | 53 | Male | | | | + | | + | | | | | | 249 | 6180 | D, H, C | XII | 44 | Male | | | | + | | | | | | + | | 182 | 5180 | TH, C | XIII | 49 | Male | | | | | | | | | | | | 314 | 6260 | | XIV | 64 | Male | | | | + | | + | | | | | | 183 | 4780 | | XV | 42 | Male | | | | | | | | | | | | 148 | 3680 | | XVI | 62 | Male | | | | + | + | | | | | | | 372 | 6040 | H | XVII | 41 | Female | | | | | | | | | | | | 174 | 4090 | | XVIII | 68 | Female | | | | | | | | | | | | 191 | 5450 | TH | XIX | 61 | Female | | + | | | + | | | | | + | + | 109 | 6880 | D, TH, C | XX | 67 | Female | + | + | + | | + | | | | | + | | 270 | 7510 | D, TH | XXI | 63 | Female | | + | + | | + | | | | | + | | 142 | 5120 | H, TH | XXII | 36 | Female | | | | | | | + | | | | | 87 | 3800 | | XXIII | 47 | Female | | | | | | | | + | + | | | 126 | 4300 | H, TH | XXIV | 23 | Female | | | | | | | | | | | | 158 | 5120 | | XXV | 69 | Female | | | | | | | | | | | | 143 | 4700 | | XXVI | 38 | Female | | | | | | + | | | | | + | 180 | 4210 | | XXVII | 63 | Female | + | | | + | + | | | | | + | + | 199 | 4980 | D, TH | XXVIII | 59 | Female | | | + | | + | + | + | | | + | + | 86.2 | 3880 | | XXIX | 50 | Female | | | | | | | | | + | + | | 231 | 5430 | C | XXX | 59 | Female | | | | + | | | | | | | | 100 | 4390 | D | XXXI | 65 | Female | | | + | | + | + | + | | | + | + | 41 | 2220 | TH, C | XXXII | 70 | Female | | | | | + | | | | + | + | | 163 | 5550 | TH |
|
|
CB: calcium channel blocker; RA: medications affecting the renin-angiotensin system (C09); LP: lipid medication (C10); GB: gall bladder (A05A); BAA: beta-adrenoreceptor antagonists (C07A); AD: androgens (G03B); PG: hormones for pituitary gland (H01A, H01B); HT: hormones for hypothalamus (H01C); PA: psychoanaleptics (N06); TT: thyroid therapy (H03); SC: systemic corticosteroids (H02A). D: self-reported diabetes mellitus or antidiabetic therapy (ATC code: A10), H: hypertension (defined as diastolic >90 mmH or systolic pressure >140 mmHg or hypertensive medication (ATC code: C02)); K: self-reported chronic kidney disease; TH: self-reported chronic thyroid disease; C: self-reported cancer. IGF-I: insulin-like growth factor-1.
|